EXPERT VIEW: What does the future hold for clinical trials data and pharmacovigilance in Europe?
Europe is leading the way when it comes to transparency in clinical trials data. That’s the view of regulatory lawyer Vincenzo Salvatore, senior counsel at Sidley Austin and a member of the firm’s EU Life Sciences Regulatory team, who spoke to The Pharma Letter’s Sophie Flowers.
Mr Salvatore was speaking as the European Union is in the process of discussing changes to the rules governing publication of clinical trials data, emphasizing a desire for greater transparency. With the European parliament elections next year, the current rulers are in a rush to push through legislation before May 2014.
Demand for transparency and quality
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze